Type
|
Public |
---|---|
Traded as | NASDAQ: PDLI |
Industry | Biotechnology |
Key people
|
John McLaughlin (CEO) |
Revenue | $590.4 million (2015) |
Website | pdl |
John McLaughlin (CEO)
Peter Garcia (CFO)
Cary Queen (Founder, former vice-president in charge of research)
PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.
Protein Design Labs had been founded in 1986 and was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included rituximab (Rituxan), bevacizumab (Avastin), and palivizumab (Synagis). It held its initial public offering in 1992 and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty. Daclizumab became the first humanized monoclonal antibody approved for human use in 1997. PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001. In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year. These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008; in 2007 those royalty payments were around $220 million.
One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009; Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year. The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2020 | 2020-11-11 | -0.01 | 0.00 |
Q2 2020 | 2020-08-06 | -0.43 | -0.11 |
Q1 2020 | 2020-05-07 | -0.26 | -0.15 |
Q4 2019 | 2020-03-11 | -0.48 | -0.48 |
Q3 2019 | 2019-11-06 | -0.16 | -0.16 |
Q2 2019 | 2019-08-07 | -0.04 | -0.07 |
Q1 2019 | 2019-05-09 | 0.05 | -0.07 |
Q4 2018 | 2019-03-14 | 0.11 | 0.12 |
Q3 2018 | 2018-11-06 | 0.18 | 0.18 |
2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
2016-02-23 | Lower Price Target | Cowen and Company | Market Perform | $5.50 to $4.00 |
2016-02-23 | Lower Price Target | RBC Capital | Sector Perform | $5.00 to $4.00 |
2016-02-23 | Lower Price Target | Royal Bank Of Canada | Sector Perform | $5.00 to $4.00 |
2016-02-22 | Reiterated Rating | Cowen and Company | Hold | |
2016-02-02 | Lower Price Target | RBC Capital | Sector Perform | $6.00 to $5.00 |
2015-11-05 | Lower Price Target | RBC Capital | Sector Perform | $7.00 to $6.00 |
2015-10-16 | Lower Price Target | RBC Capital | Sector Perform | $8.00 to $7.00 |
2014-08-20 | Boost Price Target | Cowen and Company | $7.00 to $8.00 | |
2009-03-27 | Upgrade | Lazard Capital Mkts | Hold to Buy | $8 |
2009-03-03 | Reiterated | Wedbush Morgan | Buy | $15 to $9 |
2009-03-03 | Reiterated | JMP Securities | Mkt Outperform | $16 to $9 |
2009-01-05 | Upgrade | JP Morgan | Underweight to Neutral | |
2008-12-10 | Reiterated | Credit Suisse | Neutral | $11 to $12 |
2008-09-11 | Downgrade | JP Morgan | Neutral to Underweight | |
2008-06-13 | Downgrade | Credit Suisse | Outperform to Neutral | |
2008-04-22 | Downgrade | Wachovia | Outperform to Mkt Perform | |
2008-04-11 | Reiterated | Credit Suisse | Outperform | $19 to $16 |
2008-03-10 | Downgrade | Susquehanna Financial | Positive to Neutral | |
2008-03-06 | Reiterated | BMO Capital Markets | Market Perform | $18 to $14 |
2008-03-05 | Downgrade | Broadpoint Capital | Buy to Neutral | |
2008-02-05 | Reiterated | Lazard Capital | Buy | $25 to $21 |
2008-02-05 | Reiterated | BMO Capital Markets | Market Perform | $22 to $18 |
2008-01-10 | Reiterated | Lehman Brothers | Overweight | $26 to $21 |
1970-01-01 |
2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
2016-02-23 | Lower Price Target | Cowen and Company | Market Perform | $5.50 to $4.00 |
2016-02-23 | Lower Price Target | RBC Capital | Sector Perform | $5.00 to $4.00 |
2016-02-23 | Lower Price Target | Royal Bank Of Canada | Sector Perform | $5.00 to $4.00 |
2016-02-22 | Reiterated Rating | Cowen and Company | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PDLI 29 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 7.36M |
BlackRock Institutional Trust Company, N.A. | 5.82M |
RUSSELL FRANK CO/ | 2.67M |
Numeric Investors LLC | 1.00M |
BlackRock Investment Management, LLC | 0.68M |
TEACHERS ADVISORS INC | 0.32M |
TIAA CREF INVESTMENT MANAGEMENT LLC | 0.30M |
BlackRock Group LTD | 0.27M |
HANCOCK HOLDING CO | 0.18M |
CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. | 0.13M |
Aperio Group, LLC | 0.12M |
Nine Chapters Capital Management LLC | 0.11M |
BLACKROCK ADVISORS LLC | 86123 |
BAIRD ROBERT W & CO INC /WI/ | 66712 |
Airain ltd | 56911 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
MCLAUGHLIN JOHN PETER | 0.78% (1252785) | AAVL / PDLI / SGEN / |
GARCIA PETER S Vice President, CFO | 0.28% (455024) | BTX / MRNA / PDLI / |
Stone Christopher Lewis VP and General Counsel | 0.27% (430787) | PDLI / |
SAXE JON S | 0.26% (421680) | DRRX / PDLI / SCLN / VTGN / |
Hart Danny J Jr. Assoc Genl Counsel/Asst Sec | 0.24% (387236) | PDLI / |
Monnet Dominique President | 0.15% (240200) | PDLI / |
SANDMAN PAUL W | 0.13% (208452) | PDLI / |
SELICK HAROLD E | 0.13% (202480) | PDLI / PTGX / THLD / TRGT / |
Lindell Jody S | 0.13% (201826) | COO / PDLI / |
GRYSKA DAVID W | 0.10% (165163) | AERI / HPTX / INCY / PDLI / SGEN / |
Edick Paul R | 0.10% (160215) | DRTX / NEOS / NLNK / PDLI / SCMP / |
Saks Samuel R | 0.10% (159842) | ASPX / DEPO / PDLI / TNXP / |
Pietzke Steffen Controller and CAO | 0.09% (139587) | PDLI / |
Hasnain Faheem President & CEO | 0.08% (125000) | AMBI / PDLI / RCPT / VTL / |
MURRAY RICHARD /CA/ EVP & CSO | 0.04% (70159) | PDLI / |
LARSON CHRISTINE R VP & Chief Financial Officer | 0.04% (62049) | DVAX / PDLI / |
FRANK FRED | 0.02% (33296) | LNDC / PDLI / |
Montez David Controller and CAO | 0.02% (26719) | PDLI / |
GAGE L PATRICK Interim CEO | 0.01% (19555) | CYTK / PDLI / TTPH / |
KLEIN JOSEPH III | 0.01% (16983) | ISIS / PDLI / |
Tomlinson Bruce Chief Financial Officer | 0.01% (16509) | PDLI / |
SHAH JAISIM SVP, Mktg & Bus. Affairs | 0.01% (16125) | PDLI / SRNE / |
McCamish Mark Anthony SVP & CMO | 0.01% (14924) | PDLI / |
GUGGENHIME ANDREW SVP & Chief Financial Officer | 0.01% (13255) | DERM / PDLI / |
WILSON KAREN J VP of Finance & PAO | 0.01% (10494) | JAZZ / PDLI / |
KRUMEL CAROLINE J Vice President of Finance | 0.01% (9384) | PDLI / |